Patents Examined by Jerome D. Goldberg
  • Patent number: 6495600
    Abstract: A composition and method of preventing or inhibiting tumor growth, and of treating malignant melanoma, without toxic side effects are disclosed. Betulinic acid or a betulinic acid derivative is the active compound of the composition, which is topically applied to the situs of tumor.
    Type: Grant
    Filed: August 9, 2000
    Date of Patent: December 17, 2002
    Assignee: The Board of Trustees of the University of Illinois
    Inventors: John M. Pezzuto, Tapas K. DasGupta, Darrick S. H. L. Kim
  • Patent number: 6492352
    Abstract: A method for therapeutic or prophylactic control of Acquired Immunodeficiency Syndrome (AIDS) in which an effective dose of phosphonoformic acid or a therapeutically-acceptable salt thereof is administered to a patent.
    Type: Grant
    Filed: December 16, 1993
    Date of Patent: December 10, 2002
    Assignee: Astra Lakemedel Aktiebolag
    Inventor: Bo Fredrik Öberg
  • Patent number: 6486179
    Abstract: A method for treating neoplasms is disclosed, particularly using the &bgr;-isozyme selective PKC inhibitor, (S)-3,4-[N, N′-1,1′-((2″-ethoxy)-3′″(O)-4′″-(N,N-dimethylamino)-butane)-bis-(3,3′-indolyl)]-1(H)-pyrrole-2,5-dione or one of its salts, such PKC inhibitors enhance the clinical efficacy of oncolytic agents and radiation therapy.
    Type: Grant
    Filed: January 10, 2001
    Date of Patent: November 26, 2002
    Assignee: Eli Lilly and Company
    Inventors: Michael R. Jirousek, Lawrence E. Stramm, Douglas Kirk Ways
  • Patent number: 6486155
    Abstract: A method for inhibiting neoplasia, particularly cancerous and precancerous lesions by exposing the affected cells to isoquinoline derivatives.
    Type: Grant
    Filed: November 24, 1998
    Date of Patent: November 26, 2002
    Assignee: Cell Pathways Inc
    Inventors: Rifat Pamukcu, Gary A. Piazza
  • Patent number: 6476009
    Abstract: The present invention relates to a method of inhibiting the activity of the HIV virus in a human comprising administering to the human an effective dose of phosphonoformic acid or a therapeutically effective salt thereof.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: November 5, 2002
    Assignee: Astra Lakemedel Aktiebolag
    Inventor: Bo Fredrik Öberg
  • Patent number: 6469022
    Abstract: A combination of 9,10-dihydro-5-methoxy-9-oxo-N-[4-[2-(1,2,3,4-tetrahydro-6,7,-dimethoxy-2-isoquinolinyl)ethyl]phenyl]-4-acridinecarboxamide or a salt thereof and paclitaxel and its analogs or derivatives.
    Type: Grant
    Filed: August 17, 2000
    Date of Patent: October 22, 2002
    Assignee: Smith Kline Beecham, Corporation
    Inventor: Jan H. M. Schellens
  • Patent number: 6469045
    Abstract: The present invention comprises a group of compounds that effectively inhibit angiogenesis. More specifically, thalidomide and various related compounds such as thalidomide precursors, analogs, metabolites and hydrolysis products have been shown to inhibit angiogenesis and to treat disease states resulting from angiogenesis. Importantly, these compounds can be administered orally.
    Type: Grant
    Filed: April 7, 2000
    Date of Patent: October 22, 2002
    Assignee: The Children's Medical Center Corporation
    Inventor: Robert D'Amato
  • Patent number: 6465020
    Abstract: This invention is concerned with the clinical investigation of the therapeutic effects of garlic extracts containing allicin, diallyl disulfide, and diallyl trisulfide. The intake of garlic or therapeutically active substances such as allicin from garlic, induces immunostimulation and these active substances possess strong antitumor effects including the apoptosis of tumors, including the programmed cell death of human prostatic and bladder tumor cells. This invention claims that garlic and/or garlic extracts possess very effective therapeutic substances useful not only to treat human prostate and bladder cancers to extend life span of patients, but also to suppress or prevent bladder and prostate gland cancers.
    Type: Grant
    Filed: July 5, 2000
    Date of Patent: October 15, 2002
    Assignee: Korea Chungang Educational Foundation
    Inventors: Jun Cheon, Jejong Kim, Jungku Lee, Hankyeum Kim, Doogun Moon
  • Patent number: 6465448
    Abstract: This invention generally relates to novel compositions and methods for the treatment of certain cancers. Additionally, this invention relates to novel compositions and methods to screen drugs for the treatment of certain cancers. Specifically, the invention contemplates that temozolomide and methoxyamine, in combination or in sequence, shall be used as a treatment for certain tumors that are resistant to treatment by temozolomide alone.
    Type: Grant
    Filed: August 13, 1999
    Date of Patent: October 15, 2002
    Assignee: Case Western Reserve University
    Inventors: Stanton L. Gerson, Lili Liu
  • Patent number: 6465466
    Abstract: Use of compounds of the formula I for preparing a medicament for protecting DNA in the initial phase and/or the promoting phase of carcinogenesis and for preventing oxidative stress in patients with diseases related to free radicals are described.
    Type: Grant
    Filed: March 19, 2001
    Date of Patent: October 15, 2002
    Inventors: Jan Bergman, Lennart Möller, Hans Vallberg
  • Patent number: 6462064
    Abstract: The invention relates to the discovery that specific adamantyl or adamantyl group derivatives containing retinoid-related compounds induce apoptosis of cancer cells and therefore may be used for the treatment of cancer, including advanced cancer. Also, the present invention relates to novel adamantyl or adamantyl group derivatives containing retinoid compounds and their usage for treatment and/or prevention of cancer, keratinization disorders, dermatological conditions, and other therapies More specifically, it has been shown that such adamantyl compounds, e.g., 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthoic acid, 2-[3-(1-adamantyl)-4-methoxyphenyl]-5-benzimidazole carboxylic acid, and 6-[3-(1-adamantyl)-4,5-methylenedioxyphenyl]-2-naphthoic acid, can be used to treat or prevent cervical cancers and precancers such as cervical dysplasias, including high grade and low grade dysplasias.
    Type: Grant
    Filed: February 4, 2000
    Date of Patent: October 8, 2002
    Assignee: Galderma Research & Development S.N.C.
    Inventors: Magnus Pfahl, Xian-Ping Lu, Darryl Rideout, Hongyue Zhang
  • Patent number: 6462062
    Abstract: Benzimidazole derivatives and salts and prodrugs thereof are disclosed, together with methods for the treatment of cancers or viral infections in warm blooded animals by administration of these compounds. Such compounds may be used in combination with a chemotherapeutic agent and/or a potentiator.
    Type: Grant
    Filed: September 26, 2000
    Date of Patent: October 8, 2002
    Assignee: The Procter & Gamble Company
    Inventors: James Berger Camden, James C. Quada, Jr., Joseph K. Agyin
  • Patent number: 6462087
    Abstract: The present invention provides composition having as active ingredients a stilbene derivative and a platinum coordination compound which is highly efficacious and highly safe for treating tumors, particularly for the treatment of solid or malignant tumors and thus methods of cancer and tumor treatment using the composition are also provided.
    Type: Grant
    Filed: October 3, 2000
    Date of Patent: October 8, 2002
    Assignee: Ajinomoto Co., Inc.
    Inventors: Yoshihiro Morinaga, Yukio Nihei, Yasuyo Suga, Manabu Suzuki, Kazuo Ohishi, Akira Okano
  • Patent number: 6451849
    Abstract: This invention relates to methods for prevention of cancers, certain non-cancer, hormone dependent diseases and/or cardiovascular diseases in a person, based on administering of hydroxymatairesinol to said person. The invention also concerns a method for increasing the level of enterolactone or another metabolite of hydroxymatairesinol in a person's serum thereby causing prevention of a cancer or a certain non-cancer, hormone dependent disease in a person, based on administering of hydroxymatairesinol to said person. Furthermore, this invention relates to pharmaceutical preparations, food additives and food products comprising hydroxymatairesinol.
    Type: Grant
    Filed: March 30, 1999
    Date of Patent: September 17, 2002
    Assignee: Hormos Nutraceutical Oy Ltd.
    Inventors: Markku Ahotupa, Chester Eckerman, Lauri Kangas, Sari Mäkelä, Niina Saarinen, Risto Santti, Anni Wärri
  • Patent number: 6448288
    Abstract: The invention relates to the use of cannabinoid compounds (derivatives of tetrahydrocannabinol) for decreasing cell proliferation in a mammal.
    Type: Grant
    Filed: May 8, 2001
    Date of Patent: September 10, 2002
    Assignee: University of Massachusetts
    Inventors: Sumner H. Burstein, Lawrence D. Recht, Robert B. Zurier
  • Patent number: 6448287
    Abstract: Lipoic acid and/or its water soluble salt is used to treat cancer, alone or in combination with ascorbic acid (vitamin C). Alone or in combination, it was shown to be effective on in vitro tumors and mouse tumors. The agents can be administered safely, and have been used effectively in case studies.
    Type: Grant
    Filed: July 23, 1999
    Date of Patent: September 10, 2002
    Assignee: The Center for the Improvement of Human Functioning, INTL., Inc.
    Inventors: Joseph J. Casciari, Neil H. Riordan
  • Patent number: 6444658
    Abstract: The present invention relates to methods for preventing the development of epithelial ovarian cancer by administering a Vitamin D compound in an amount capable of increasing apoptosis in non-neoplastic ovarian epithelial cells of the female subject.
    Type: Grant
    Filed: January 7, 2000
    Date of Patent: September 3, 2002
    Assignee: New Life Pharmaceuticals Inc.
    Inventors: Gustavo C. Rodriguez, Regina Salas Whitaker
  • Patent number: 6440998
    Abstract: Pharmaceutical compositions having enhanced antitumor activity or reduced side effects. The compositions include both (A) a known active substance having antitumor effect or a pharmaceutically suitable salt thereof and (B) an effective amount of a hydroximic acid derivative of formula (I) or a therapeutically useful acid addition salt thereof. Also disclosed are methods for reducing side effects in patients requiring treatment for tumors.
    Type: Grant
    Filed: February 17, 2000
    Date of Patent: August 27, 2002
    Assignee: N-Gene Research Laboratories, Inc.
    Inventor: Balázs Sumegi
  • Patent number: 6440981
    Abstract: A method for inhibiting the growth of neoplastic cells by exposure to 2,9-disubstituted purin-6-ones.
    Type: Grant
    Filed: July 30, 2001
    Date of Patent: August 27, 2002
    Assignee: Cell Pathways, Inc.
    Inventors: Rifat Pamukcu, Gary A. Piazza
  • Patent number: 6441029
    Abstract: A method of inhibiting the growth of tumor cells is disclosed. In one embodiment, this method comprises the step of exposing tumor cells to an effective amount of a composition comprising at least two compounds selected from the group consisting of tocotrienols, statins and ionones.
    Type: Grant
    Filed: June 5, 2000
    Date of Patent: August 27, 2002
    Assignee: Wisconsin Alumni Research Foundation
    Inventor: Charles E. Elson